UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

The Lancet (British edition), 2019-07, Vol.394 (10192), p.29-38

2019

Volltextzugriff (PDF)

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3892-3901

2007

Volltextzugriff (PDF)

Mitigation of alkali-silica reaction by microbially induced CaCO3 protective layer on aggregates

Construction & building materials, 2022-04, Vol.328, p.127065, Article 127065

2022

Volltextzugriff (PDF)

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

The Lancet (British edition), 2021-07, Vol.398 (10297), p.314-324

2021

Volltextzugriff (PDF)

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

The New England journal of medicine, 2021-07, Vol.385 (1), p.46-58

2021

Volltextzugriff (PDF)

Arc plasma synthesis of carbon nanostructures: where is the frontier?

Journal of physics. D, Applied physics, 2011-05, Vol.44 (17), p.174006

2011

Volltextzugriff (PDF)

Efficient inhibition of ASR by microbially induced calcium carbonate precipitation on aggregates at a low degree of saturation

Journal of Building Engineering, 2024-05, Vol.84, p.108516, Article 108516

2024

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4522-4529

2009

Volltextzugriff (PDF)

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

The cancer journal (Sudbury, Mass.), 2009-09, Vol.15 (5), p.395-400

2009

Volltextzugriff (PDF)

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

Clinical cancer research, 2010-03, Vol.16 (5), p.1634-1641

2010

Volltextzugriff (PDF)

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Cancer, 2008-04, Vol.112 (7), p.1529-1537

2008

Volltextzugriff (PDF)

Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation

Endocrinology (Philadelphia), 1998-03, Vol.139 (3), p.1197-1207

1998

Volltextzugriff (PDF)

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

Annals of hematology, 2010-11, Vol.89 (11), p.1133-1140

2010

Volltextzugriff (PDF)

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Cancer, 2005-05, Vol.103 (9), p.1932-1938

2005

Volltextzugriff (PDF)

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

Clinical cancer research, 2007-12, Vol.13 (24), p.7480-7486

2007

Volltextzugriff (PDF)

Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome

Clinical lymphoma, myeloma and leukemia, 2011-02, Vol.11 (1), p.44-49

2011

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

Clinical lymphoma & myeloma, 2008-12, Vol.8 (6), p.352-355

2008

Volltextzugriff (PDF)

Experimental Investigation of Mechanical Properties of Centrifugal Concrete in Circular Pipes

Journal of materials in civil engineering, 2017-04, Vol.29 (4)

2017

Volltextzugriff (PDF)

Preparation of Artificial Antigen and Egg Yolk-derived Immunoglobulin (IgY) of Citrinin for Enzyme-Linked Immunosorbent Assay

Biomedical and environmental sciences, 2009-06, Vol.22 (3), p.237-243

2009

Volltextzugriff (PDF)

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1275-1284

2023

Volltextzugriff (PDF)

A knowledge-based model for nitrogen management in rice [Oryza sativa] and wheat [Triticum aestivum]

Plant production science, 2009-01, Vol.12 (1), p.100-108

2009

Volltextzugriff (PDF)

Research and application: liquid crystal devices fabricated by single-exposure photoalignment

Ye jing yu xian shi, 2021-06, Vol.36 (6), p.761-771

2021

Volltextzugriff (PDF)

Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089

Cancer epidemiology, biomarkers & prevention, 1999-03, Vol.8 (3), p.241

1999

Volltextzugriff (PDF)

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Annals of the New York Academy of Sciences, 2015-11, Vol.1358 (1), p.82-94

2015

Volltextzugriff (PDF)

1 – 25 von 489

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(395)
Mit Volltextzugriff
(405)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(303)
Life Sciences & Biomedicine
(155)
Technology
(103)
Humans
(95)
Physical Sciences
(76)
Engineering
(56)
Male
(52)
Female
(49)
Chemistry
(36)
Middle Aged
(34)
Materials Science
(33)
Oncology
(33)
Adult
(32)
Physics
(32)
Materials Science, Multidisciplinary
(27)
Science & Technology - Other Topics
(26)
Animals
(24)
Gastroenterology & Hepatology
(23)
Aged
(20)
Chemistry, Multidisciplinary
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Mitigation of alkali-silica reaction by microbially induced CaCO3 protective layer on aggregates

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Arc plasma synthesis of carbon nanostructures: where is the frontier?

Efficient inhibition of ASR by microbially induced calcium carbonate precipitation on aggregates at a low degree of saturation

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

Experimental Investigation of Mechanical Properties of Centrifugal Concrete in Circular Pipes

Preparation of Artificial Antigen and Egg Yolk-derived Immunoglobulin (IgY) of Citrinin for Enzyme-Linked Immunosorbent Assay

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)

A knowledge-based model for nitrogen management in rice [Oryza sativa] and wheat [Triticum aestivum]

Research and application: liquid crystal devices fabricated by single-exposure photoalignment

Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Suchergebnisse filtern